Jornal Vascular Brasileiro
https://jvascbras.org/article/doi/10.1590/S1677-54492012000200010
Jornal Vascular Brasileiro
Artigo Original

Inhibition of nitric oxide synthesis for four days induces vascular abnormalities and myocardial infarct areas but not significant arterial hypertension

Ricardo Xavier-Vidal

Downloads: 0
Views: 836

Abstract

BACKGROUND: Nitric oxide is an endothelium vasorelaxing factor and at least in some cases is the main cause of arterial hypertension, which is one of the most important risk factors of cardiovascular diseases. In Brazil, cardiovascular diseases are the first cause of mortality, representing about 30% of the total deaths. The L-NAME (Nω-nitro-arginine-methyl-ester) blocks the nitric oxide synthesis necessary to maintain the normal arterial pressure. OBJECTIVE: To study lesions in myocardium due to the inhibition of nitric oxide synthesis during four days (via L-NAME oral administration, concentration: 75 mgs versus 100 mL-1). METHODS: Fourteen normotensive young adults Wistar rats were submitted, during four days, to L-NAME. Six rats were utilized as the Control Group. At day 4 of the experiment, the animals were anesthetized, weighed, and their thoraxes were opened, and the cardiotomy was performed. The hearts were weighed, fixed, and processed using routine methods, and they were sectioned in 3 µm and stained. RESULTS: Abnormalities were observed in the wall of arterial vessels of any dimension, as vascular damage with increasing wall thickness related mainly to proliferation of arterial smooth muscle cell in submitted animals. Proliferation of cells in the intimal layer and its thickening were also observed in small arterial vessels (arteriole). Infarct areas were present. CONCLUSIONS: The present data suggested that inhibition of nitric oxide synthesis for four days induces vascular abnormalities and myocardial infarct areas, but not arterial hypertension.

Keywords

nitric oxide, L-NAME, hypertension, cardiopathy, heart

References

Numaguchi K, Egashira K, Takemoto M. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26(1):957-62.

Ignarro L.J. Role of nitric oxide in the pathophysiology of hypertension; physiology and pathophysiology of nitric oxide. Kidney Intern. 1996;49(^s55):S2-5.

Moreno Jr H, Nathan LP, Costa SKP. Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide. Eur J Pharmacol. 1995;287:93-6.

Moreno Jr. H, Nathan LP, Metze K. Non-specific inhibitors of nitric oxide synthase cause myocardial necrosis in the rat. Clin Exper Pharmacol Physiol. 1997;24:349-52.

Xavier-Vidal R, Madi K, Lima RJ, Nádia MS, Reis AA, Paes LS. Estudo anatomo-patológico experimental em miocárdio de animais submetidos à hipertensão arterial via bloqueador da síntese do óxido nítrico. Rev Port Cardiol. 1999;18(4):381-91.

Xavier-Vidal R, Madi K, Reis AA. Hydralazine reduces myocardial tissue damage in rats submitted to chronic inhibition of systemic nitric oxide synthesis during days 4, 14 and 28. J Bras Patol Med Lab. 2003;39(3):245-52.

Xavier-Vidal R, Carvajal SSR, Cunha SB, Madi K. Multivariate Allometry and myocardium abnormalities during experimental systemic nitric oxide blockage. J Brasil Patol Med Lab. 2004;40(3):203-8.

Xavier-Vidal R. Anatomic-pathological study of the myocardium submitted to chronic Inhibition of the systemic synthesis of Nitric Oxide (NO) on the structure of the heart. CLINICS. 2005;60(2):85-92.

Xavier-Vidal R, Carvajal SSR, Cunha SB, Madi K. Multivariate allometry using stereological data belongs from l-name model induces hypertension, cardiac hypertrophy and stereological myocardium lesions (day 35). Braz J Investig Pathol Morphol Morphom. 2006;1(1):7-14.

Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO, Cannon . Impaired endothelium-dependent vasodilatation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91(6):1732-8.

Brush JE, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endothelium-dependent vasodilatation in patients with essential hypertension. J Am Coll Cardiol. 1992;19:809-15.

França MF. Efeitos da L-arginina por via endovenosa sobre a pressão arterial sistema renina-angiotensina, hemodinâmica renal e excreção de sódio em hipertensos essenciais. 1995.

Cockcroft JR, Chowienczk PJ, Benjamin N, Ritter TJ. Abnormal endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med. 1994;330:1036-40.

Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension. 1997;29(2):235-41.

Ribeiro MO, Antunes E, De Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension. 1992;20:298-303.

Felix J, Ramires A, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockage. J Mol Cell Cardiol. 1998;30:475-83.

Xavier-Vidal R, Madi K, Menezes FG. Hydraulic Pletismography: detailed confection of a low cost tail-cuff equipment used to measure arterial pressure in conscious small mammals. Braz J Investig Pathol Morphol Morphom. 2006;1(1):33-44.

Xavier-Vidal R. Avaliação morfológica, à microscopia óptica convencional, do miocárdio ventricular de ratos Wistar submetidos ao bloqueio sistêmico da síntese do óxido nítrico. .

Xavier-Vidal R. Alterações morfológicas do miocárdio devidas a hipertensão arterial induzida por inibidor da síntese do óxido nítrico: Estudo experimental em ratos. .

Xavier-Vidal R, Madi K. A hipertensão arterial e a hipertrofia cardíaca com ênfase ao uso experimental de bloqueadores da síntese do óxido nítrico: uma breve revisão. UNIMAR. 1997;19(2):593-610.

Xavier-Vidal R. Hipertrofia cardíaca durante a inibição sistêmica experimental da síntese do óxido nítrico. Rev Cient C Univ Barra Mansa. 2002;3(6):54-63.

Xavier-Vidal R. O Método Estereológico dirigido aos estudos Biológicos e Biomédicos; Teoria e Prática com uso do Modelo Experimental L-NAME de bloqueio sistêmico da síntese do óxido nítrico. Braz J Investig Pathol Morphol Morphom. 2006;1(3):31-53.

Soubrier F. Nitric oxide synthase genes; candidate genes among many others. Hypertension. 1999;33:924-6.

Stauss HM, Mafz R, Mrowka R, Persson PB. Blood pressure control in eNOS knock-out mice: comparison with other species under NO blockade. Acta Physiol Scand. 2000;168:155-60.

Kolpakov V, Gordon D, Thomas JK. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res. 1995;76(2):305-9.

Hocher B. Endothelin sustem-dependent cardiac remodeling in renovascular hypertension. Hypertension. 1999;33:816-22.

Contran RS, Kumar V, Robbins SL, Robbins . Pathologic basis of disease. 1999.

Xavier-Vidal R, Madi K. Comparação entre os miocárdios ventriculares direito e esquerdo durante o período fetal humano: Avaliação Estereológica. Arq Bras Cardiol. 1999;72(5):587-92.

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
5ddd361c0e88250c061da3ea jvb Articles
Links & Downloads

J Vasc Bras

Share this page
Page Sections